BMSSC
CNTA

B. Metzler seel. Sohn & Co’s Centessa Pharmaceuticals CNTA Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,432
Closed -$961K – 724
2025
Q4 		$961K Buy
+38,432
New +$973K 0.01% 547

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

B. Metzler seel. Sohn & Co's CNTA Position: Q1 2026 in Review

B. Metzler seel. Sohn & Co sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 38,432 shares — an estimated $961K sold.

B. Metzler seel. Sohn & Co first reported a position in CNTA in Q4 2025 and held it in 1 quarter. The position peaked at $961K in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • B. Metzler seel. Sohn & Co reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 38,432 Centessa Pharmaceuticals shares in Q1 2026, an estimated $961K.
  • B. Metzler seel. Sohn & Co first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • B. Metzler seel. Sohn & Co's Centessa Pharmaceuticals position peaked at $961K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2026, filed 8 May 2026.